A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild
to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a
daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be
observed for an additional 6 weeks.